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Objective: To describe the quantitative treatment outcomes of patients undergoing
acoustic coordinated reset (CR) neuromodulation at a single independent audiology
practice over a 22- to 26-week period as part of an open label, non-randomized, non-
controlled observational study.
Methods: Sixty-six patients with subjective tonal tinnitus were treated with acoustic
CR neuromodulation with a retrospective review of patient records being performed
in order to identify changes of visual analog scale (VAS, n=66) and in the score of
the tinnitus handicap questionnaire (THQ, n=51). Patients had their tinnitus severity
recorded prior to the initiation of therapy using the tinnitus handicap inventory in order
to categorize patients into slight up to catastrophic impact categories. THQ and VAS
for tinnitus loudness/annoyance were obtained at the patient’s initial visit, at 10–14 and
22–26weeks.
Results: Visual analog scale scores were significantly improved, demonstrating a 25.8%
mean reduction in tinnitus loudness and a 32% mean reduction in tinnitus annoyance
with a clinically significant reduction in percept loudness and annoyance being recorded
in 59.1 and 72.7% of the patient group. THQ scores were significantly improved by 19.4%
after 22–26weeks of therapy compared to baseline.
Conclusion: Acoustic CR neuromodulation therapy appears to be a practical and
promising treatment for subjective tonal tinnitus. However, due to the lack of a control
group it is difficult to reach an absolute conclusion regarding to what extent the
observed effects are related directly to the acoustic CR neuromodulation therapy. Also,
as the observed patient group was made up of paying clients it is unknown as to
whether this could have caused any additional placebo like effects to influence the final
results.
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Introduction
Tinnitus is the involuntary perception of sound, in the absence of
corresponding auditory stimuli, which is perceived as originating
within an individual’s ears or head. This phenomenon can affect
all age groups (1), but is more likely to affect individuals who are
over the age of 60 (2).
There is a strong evolving body of evidence that suggests that
subjective tinnitus perception is linked to some form of peripheral
audiological insult. Even subjects who have normal audiometric
thresholds have been shown to have outer hair cell damage (3)
and dead cochlea regions (4). This peripheral damage is thought
to result in central neural plastic changes that affect the bal-
ance between excitatory and inhibitory processes leading to a
potential promotion of increased afferent activity (5) and neural
synchronicity (6). It is interesting to note that tinnitus generation
is unlikely to be the result of an abnormally enhanced or hyperac-
tive nerve firing pattern originating from the peripheral auditory
system as sectioning of the auditory nerve does not, typically,
eliminate tinnitus in pre-existing cases (7). It has also been noted
that cochlea pathology causes a reduction in spontaneous firing
rates in mammalian auditory nerve fibers (8). These observations
serve to implicate activity changes in central structures as being
the causal factor for the phantom percept generation. Cortical
map reorganization has previously been suggested as being a
central correlate for the emergence of tinnitus (9). However, MEG
data demonstrating altered spectral power, in subjects experienc-
ing tinnitus, suggest that this does not adequately explain the
emergence of the percept in a satisfactory manner (4).
Various authors have suggested that increased auditory neu-
ral synchrony, due to a loss of inhibition, may be the cause
of altered spectral power in human magnetoencephalogra-
phy/electroencephalography (MEG/EEG) frequency bands. An
important study investigating spontaneous brain activity in
humans with tinnitus discovered an altered pattern of activity in
the lower frequency EEG range with an increase of slow-wave (δ–
θ) activity along with a decrease in α power within the temporal
lobes (10). The perception of tinnitus intensity has actually been
linked to the level of δ activity in temporal regions (11) with
transient reductions in tinnitus loudness potentially beingmarked
by concomitant reductions of δ band power (12). There is also
data from studies that show auditory cortical γ band activity to
be strongly increased, for noise exposed subjects, within the very
early stages of tinnitus onset (13). Although it is still unclear if
this elevation in γ band activity is influenced by noise-induced
hearing loss. It is also important to note that studies reporting
that altered spectral power, as measured by EEG/MEG, as being
a neurological correlate of subjective tinnitus would benefit from
being independently repeated with larger subject populations and
appropriate controls.
However, it is important to note that there is a growing amount
of evidence that implies that the actually salient conscious percep-
tion of tinnitus requires the involvement of a significant network
of brain areas (14, 15). MEG has been used to investigate long-
range cortical networks of individuals with tinnitus and demon-
strated that information flow from the global network to the
temporal cortex correlated positively with the strength of tinnitus
distress (16). This provides evidence for the concept that percept
salience is linked to an altered functional interaction between
auditory and non-auditory brain areas.
There is currently no European Medicines Agency (EMA) or
Food and Drug Administration (FDA) approved pharmacother-
apies available for the treatment of subjective tinnitus. There is
also no internationally agreed standardization relating to patient
care. Treatments that are commonly utilized in order to improve
quality of life include patient counseling (regarding etiology and
prognosis), hearing aids, sound therapy, and cognitive behavioral
therapy (17). However, with the possible exception of cognitive
behavioral therapy, there is a lack of sufficiently large randomized
control trials to demonstrate the efficacy of other commonly used
interventions (18).
Acoustic coordinated reset (CR) neuromodulation is a non-
invasive desynchronizing stimulation therapy that aims at
counteracting pathological neural synchrony in subjects with
subjective tonal tinnitus (6, 19). The CR algorithm has been
developed computationally and is designed to desynchronize
neural networks by reducing the strength of synaptic connectiv-
ity between neurones within the cell population (6, 20, 21). In
order to desynchronize a synchronized focus in the tonotopically
organized auditory cortex, four acoustic tones are delivered with
different frequencies centered on the characteristic frequency of
the participant’s tinnitus percept (19). This reduction in neural
synchrony is considered to cause a decrease in the connectivity
across brain areas involved in the larger salience network (15,
22). A randomized proof-of-concept trial has provided evidence
for acoustic CR neuromodulation to be an effective therapy for
tinnitus by demonstrating a significant improvement in visual
analog scale (VAS) scores and tinnitus questionnaire (TQ) out-
come measures scores for 75% of patients (19). EEG recordings
for this study also demonstrated a change in pathologically altered
power spectra, specifically for α, γ, and δ bandwidths, to a more
normative level within a network of brain areas (19, 23) alongwith
a significant reduction of abnormal effective connectivity (15) and
cross-frequency coupling (24)within a tinnitus-related network of
brain areas. It is also interesting to note that a significant number
of trial participants also experienced a reduction in the character-
istic frequency of their tinnitus over the course of the study (19).
The results obtained in the randomized proof-of-concept trial (19)
were confirmed in a real life study in 200 patients suffering from
chronic tonal tinnitus (25).
This article reports the experience of a cohort of adult patients
suffering from chronic subjective tonal tinnitus when treated
with acoustic CR Neuromodulation over a 22- to 26-week period
within an independent audiology clinic setting.
Methods
Subjects
A total of 66, fee paying, participants (44 male and 22 female)
ranging in age from 31 to 76 years (with a mean of 57 years and
a SD of 13 years) completed 22–26weeks of therapy. Twenty-one
subjects were pre-existing hearing aid users who reported that
their prescriptions improved their quality of life, 28 subjects did
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FIGURE 1 | (A) Mean hearing thresholds and SD and (B) THI based tinnitus severity for the n= 66 subjects.
not have a sufficient loss to warrant the use of amplification,
and 17 subjects had tried hearing aids in the past 4 years but did
not report that they had benefited from their prescriptions. Pure
tone audiometry revealed subjects to have sensorineural hearing
losses, which ranged frommild to moderate – severe (Figure 1A).
No conductive or mixed hearing losses were recorded from the
patient group. All participants presented with tinnitus as their
primary complaint with the length of time since tinnitus onset
ranging from 3months to 27 years (with a mean of 7 years and
an SD of 8 years). Forty-two of the subjects had received tinni-
tus therapy previously via audiologists and psychologists in both
independent and socialized healthcare clinics. The specific type of
therapy utilized in these centerswas diverse in nature and included
diverse counseling methods, hearing aid prescriptions, tinnitus
retraining therapy, sound therapies, and cognitive behavioral
therapy.
The level of patient tinnitus severity was measured prior to
the initiation of therapy using the tinnitus handicap inventory
(THI) (26). Scoring revealed patients to be experiencing a com-
plete range of severities from slight (0–16 points) to catastrophic
(78–100 points, Figure 1B). The mean pre treatment THI score
for all 66 patients was 51 (with an SD of 20). There were a total
of eight patients who recorded a 0–16 point score with respect
to their pre treatment THI, which is a category that has been
suggested, by the THI questionnaire authors, to potentially be
below the threshold of clinical significance. These low category
patients did, however, report of the tinnitus percept to be suf-
ficiently bothersome to warrant their engagement in structured
therapy and determined to proceed with the intervention at their
discretion.
Patients were excluded from engaging in acoustic CR neuro-
modulation therapy if they experienced a dominant tinnitus pitch
<0.2 or >10 kHz, objective tinnitus, tinnitus that was co morbid
with any acute craniomandibular or cervical–vertebral disorders,
atonal tinnitus percept, had a history of Ménière’s disease, symp-
tomatic otology disorders, any history of cervical or mandibular
disorders, brainstem diseases or diagnosed psychiatric disorders,
or if they were undergoing another structured treatment for
tinnitus.
Questionnaire and Outcome Measurement
Visual analog scale for perceived tinnitus loudness and annoyance
were utilized as the primary outcomemeasurement. VAS loudness
and VAS annoyance tinnitus metrics have demonstrated a signifi-
cant convergent validity with the TQ and test–retest reliability has
determined the minimum identifiable clinical difference (MICD)
to be 10 points for a 100 point VAS scale (22, 27).
The tinnitus handicap questionnaire (THQ) (28) was used as
the secondary outcome measurement. The THQ is a validated
outcomemeasure, with a 0–2700 range (α= 0.95; r= /0.89) that is
sensitive to change in tinnitus-related symptoms over time (29). Its
validity, factor structure, and reliability have been independently
evaluated as a sensitive metric with a test–retest reliability of 0.93
(30). THQ data from a published study of tinnitus maskers were
used to estimate MICD for the metric (31) found that a difference
in mean THQ score of 194 was considered significant, and repre-
sented a medium effect size. For the THQ, with a maximum score
of 2700, this would equate to an individual score change of 7.1 or
greater on a normalized scale (0–100) to be clinically significant.
In our study, a normalized scale (0–100) was used.
Visual analog scale and THQ were recorded at the partici-
pant fitting appointment and then at their 12–14weeks follow up
appointment and finally at their 22–26weeks follow up appoint-
ment. Prior to completing VAS and THQ, patients were required
to cease active stimulation for a minimum of 15min. Results
were obtained from a total of 66 patients for VAS and 51 patients
for THQ.
Fitting and Stimulation Protocol
The subject’s characteristic tinnitus frequency was assessed using
a manufacturer designed pure tone matching protocol, where the
intensity and frequency of thematching tonewere controlled by an
audiologist and the patient. Thismethodwas found to be very time
consuming with the approximate unilateral pitch matching time
being of 45min in duration. Pitch matching results were recorded
as being repeatable towithin5% accuracy; however, thismethod
of therapy would benefit from utilizing a pitch matching method
that can be completed in shorter period of time.
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Patients were then stimulated for a 22- to 26-week treatment
period using a portable acoustic device (T30 CR neurostimulator)
coming with ear phones adapted from receiver-in-the-ear-canal
(RIC) hearing aids that ensured that the subject’s auditory meatus
was not occluded by the headphone receiver. All participants
received stimulation for 4–6 h/day either continuously or divided
into several sessions of a time period no shorter than one hour.
The temporal, spatial, and frequency characteristics of the gen-
erated tones were determined via the CR algorithm [Ref. (19),
group 1]. This formula reflects the non-linear tonotopic organiza-
tion of the auditory cortex and utilizes the matched frequency of
each participant’s tinnitus percept. Acoustic CR neuromodulation
employs the use of an equal number of tones that are generated
above and below the subject’s specific tinnitus frequency. The
stimulation tones are matched for loudness and presented at
approximately 10–15 dBSPL above threshold. The presentation
cycle consists of four tones played in a randomized order over
three stimulation cycles followed by a pause in stimulation that
lasts the equivalent time period of two presentation cycles. The
cycle repetition rate was 1.5Hz.
Patients were seen at four subsequent follow up appointments,
post fitting, in order to have the characteristic pitch of their
tinnitus rematched. A readjustment of the stimulation parameters
could occur at these visits if the matched tinnitus frequency had
changed.
Statistical Method
Descriptive statistics was used for each of the four variables (THQ,
VAS loudness, VAS annoyance, and tinnitus pitch) and the three
time points. A paired t-test was used to compare the variables to
mid and endof treatment scores. The effect sizewas also calculated
for all outcome measures using the mean and SD of the scores.
Results
Tinnitus Loudness and Annoyance
The recording of VAS scores at follow up appointments, compared
to baseline, revealed a significant reduction for both tinnitus
loudness and annoyance. VAS scores for tinnitus loudness reduced
by an average of 16.54 and 25.8% at the 12- to 14- and 22- to 26-
week treatment mark respectively (p< 0.01 compared to baseline,
see Figure 2A) with 59.1% of patients demonstrating a clinically
significant reduction in symptoms at 22–26weeks. Mean VAS
scores for tinnitus annoyance were reduced by 21.3 and 32% at
12–14 and 22–26weeks, respectively (p< 0.01 compared to base-
line, Figure 2B). About 72.7% of participants experienced a clin-
ically significant reduction for VAS annoyance after 22–26weeks
of treatment.
The effect size using mean difference and SD from base line
to 22–26weeks was 0.81 for VAS tinnitus loudness and 1.09 for
VAS tinnitus annoyance. These values represent a large treatment
effect.
Tinnitus Handicap Questionnaire Data
Tinnitus handicap questionnaire scores were significantly reduced
compared to baseline. THQ scores reduced by an average of 10.3%
at 12–14weeks (p< 0.01 compared to baseline, Figure 2C). The
clinical effect became more robust at 22–26weeks with scores
reducing by an average of 19.4% (p< 0.01 compared to baseline,
see Figure 2C). About 58.8% of patients experienced a clinically
significant reduction in THQ score at 22–26weeks. The effect
size using mean difference and SD from base line to 22–26weeks
was 0.6 for the THQ. This value represents a medium treatment
effect.
Tinnitus Pitch Match Frequency
Sixty-four of the patients surveyed experienced a change in
their pitch matched percept frequency, at 12 and 24weeks,
which required the neurostimulator system to be retuned to the
newly perceived frequency. Tinnitus pitchmatched frequency was
reduced by 7.3% (mean reduction of 477.5Hz) at 12–14weeks
(p< 0.01 compared to baseline) and by 11.1% (mean reduction
of 674.3Hz) at 22–26weeks (p< 0.01 compared to baseline).
Analysis of Outcome Scores for Patients with
Slight or Untroubling Tinnitus
A small number of subjects within this investigation recorded
a THI score of 16 points or less, which is described as being
FIGURE 2 | (A) VAS loudness scores, (B) VAS annoyance scores and (C) THQ scores for the three visits (initial visit, 10–14weeks and 22–26weeks visit). Data are
visualized using whisker plots, significant changes are indicated by the stars (**p<0.01).
Frontiers in Neurology | www.frontiersin.org March 2015 | Volume 6 | Article 544
Williams et al. A review of clinical outcomes in an independent audiology practice setting
only audible in quiet environments and having no impact upon
sleeping or daily activities (32). Of the seven patients who
recorded a THQ at 24weeks no beneficial clinical effect was
revealed with scores remaining remarkably static at both outcome
appointments (mean change at 24weeks was 5.9%). VAS scores
were recorded from the same individuals plus one additional
patient at 24weeks. Mean scores for tinnitus loudness and annoy-
ance were shown to decrease by 9.9 and 14.0%, respectively, by
24weeks.
Discussion
The primary objective of this article is to report whether tinnitus
sufferers could experience a reduction in tinnitus symptoms from
acoustic CR neuromodulation therapy when it is delivered in an
outpatient setting. The data for this small sample group demon-
strate a statistically significant and clinically relevant concordant
decrease of VAS scores for tinnitus loudness/annoyance and THQ
scores. A similar reduction of tinnitus loudness and distress has
been shown in a randomized proof-of-concept trial (19), an out-
patient study (TRI conference 2011, Buffalo, NY, USA, Abstract
H. Wurzer) and in a real life study in 200 patients suffering from
chronic tonal tinnitus (25). The reduction of tinnitus loudness and
annoyance VAS scores, within this investigation, correlated with
previous work relating to tinnitusmeasurement variables (33). No
correlation, for treatment effect, was determined with respect to
patient age, gender, and audiometric configuration.
It is interesting that while patients with slight THI category
scores did not report a clinically significant score change with
respect to the THQ the psychoacoustic parameters of percept
loudness and annoyance did decrease in a much more signifi-
cant way. This may be explained by tinnitus having a very low-
emotional impact on subjects in this group making the THQ
metric very resistant to change even if tinnitus loudness and
annoyance were decreased by the therapy.
Acoustic CR neuromodulation was well tolerated with all
patients reporting, at the 24-week follow up consultation, of being
able to commit to the required daily usage routine.
Limitations to the Present Investigation
The clinical results that have been analyzed for this observa-
tional study do provide only very limited information on the
sustainability of the therapeutic effect of acoustic CR neuromod-
ulation, i.e., all measures were taken at least 15min after cessation
of stimulation in order to separate the sustained effects from
potential masker-like effects. We know that masker-like effects
usually vanish within seconds or minutes (12). We think that
this relatively short observation period after stimulation offset
is not long enough to name these effects long-term effects, but
clear sustained effects were observable. The original proof-of-
concept trial for this treatment method reported that a significant
reduction in VAS scores for percept loudness/annoyance persisted
at least for days and weeks after treatment cessation when patients
had used acoustic CR neuromodulation for a 12-week period (19).
However, the tinnitus suppression effects reduce after 4 weeks
post cessation of treatment, which indicates that a continuous
treatment period extending beyond 12weeks is appropriate in
order to achieve amaximal therapeutic effect. The same study also
reported that TQ scores progressively improved for subjects who
participated in an additional 24weeks of therapy once the blinded
trial had been completed. These results support our findings that
in an outpatient setting a treatment for 36weeks is most probably
favorable as compared to a 12weeks treatment. Treatment was
provided at charge, and this could have biased findings in some
unpredictable fashion. The THQwas used as an outcomemeasure
and although this questionnaire was developed and validated
with great rigor and is used widely [see Ref. (34)] other studies
have deemed the third factor of this tool to not be sensitive to
change (35).
This investigation would also benefit from being repeated as a
clinical trial with the addition of a control group of patients who
receive counseling and appropriate amplification as this would
provide a direct comparison intervention with which to gage the
intervention under scrutiny. This would also serve to determine
what degree of improvements may have occurred as a result of
a placebo effect. An extended test period to 52weeks or beyond
would provide more information on the sustainability of the
intervention therapeutic effect.
It is difficult to reach a final conclusion regarding towhat extent
the observed effects are related directly to the acoustic CR neuro-
modulation therapy, since no control/placebo treatment was used
in this open label, non-randomized, and non-controlled setting.
However, considering that the majority of patients were shown to
experience a progressive improvement in symptoms in contrast
to the effect of previous structured interventions serves to make
placebo induced effects improbable. A spontaneous resolution of
symptom is also improbable due to the sustainable nature of the
tinnitus percept in the majority patients surveyed as part of this
investigation.
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